The ORR of the total population was 8.5%; the mPFS was approximately 3 months, which seems similar to the results of a phase I/IIa study of nivolumab and relatlimab in patients with advanced melanoma with prior progression on anti–PD-1–/PD-L1–containing regimens (ORR: 9.2%–12.0%, mPFS: 2.1–3.2 months; ref. 18). The gene discussed is CD274; the disease is melanoma.